thumbnail_rem 1.jpg

EVA Pharma’s roots stretch back over a hundred years.

thumbnail_Pharmacy.jpeg

Pharmacy.jpeg

Our History

Our experienced leadership team keeps us on track.

thumbnail_Find_Out_More_Leaders.png

Find_Out_More_Leaders.png

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

thumbnail_1704997569480.jfif

1704997569480.jfif

Life at EVA Pharma

Having reached a landmark agreement with Gilead Sciences Inc., Eva Pharma is proud to announce that it is now a licensed manufacturer for the antiviral treatment Remdesivir in 127 countries.&nbsp;
This game-changing development establishes Eva Pharma’s position as a global leader in the battle against COVID-19. Accordingly, it will work at ‘full capacity’ while leveraging its far-reaching network to meet the onerous challenge of alacritously providing Remdesivir to all COVID-19 patients in 127 countries.&nbsp;
“This license agreement comes at a critical time as the virus has started to spread in developing countries whose health-care systems are already severely strained. It is our duty to rise to the occasion and support our fellow man as humanity collectively strives to put an end to this pandemic. Eva Pharma is therefore working tirelessly and assiduously to ensure the availability of life-saving drugs to COVID-19 patients globally”, said Eva Pharma CEO, Riad Armanious.
EVA group and Gilead are highly successful partners, having fruitfully collaborated in the past to provide accessible, affordable and high-quality treatments of otherwise lethal infectious diseases such as HIV and hepatitis C to millions of patients in Africa.&nbsp;
“We are thrilled to have been chosen to work side-by-side with Gilead sciences once more. We strongly believe that our partnership with Gilead will help us realize our vision of empowering the fight for health and well-being as a human right,’ said Armanious.
“Remdesivir” is an investigational new drug developed by Gilead Sciences. The treatment has recently been granted an emergency use authorization (EUA) to treat hospitalized COVID-19 patients in the U.S and the UK.
In addition, it is recommended for compassionate use in Europe and recently received regulatory approval in Japan. Two global clinical trials conducted to date have demonstrated positive results, reducing the recovery time for patients with COVID-19, although the full efficacy and safety of the treatment are still under investigation.
The agreement provides Eva pharma with Gilead’s technology, manufacturing process descriptions, specifications and methods in order to boost the production timeline of Remdesivir.
-ENDS-
About Gilead
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at <a id="menur6jg" class="fui-Link ___1rxvrpe f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1hu3pq6 f11qmguv f19f4twv f1tyq0we f1g0x7ka fhxju0i f1qch9an f1cnd47f fqv5qza f1vmzxwi f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="https://www.gilead.com./" href="https://www.gilead.com." target="_blank" rel="noreferrer noopener" aria-label="Link www.gilead.com.&nbsp;">www.gilead.com.&nbsp;</a>
&nbsp;
About Eva Pharma
Eva Pharma is leading international pharmaceutical company based in Cairo, Egypt and one of the fastest growing pharmaceutical company in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 140 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards. To learn more about Eva Pharma, please visit <a id="menur6ji" class="fui-Link ___1rxvrpe f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1hu3pq6 f11qmguv f19f4twv f1tyq0we f1g0x7ka fhxju0i f1qch9an f1cnd47f fqv5qza f1vmzxwi f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="http://www.evapharma.com/" href="http://www.evapharma.com/" target="_blank" rel="noreferrer noopener" aria-label="Link www.evapharma.com">www.evapharma.com</a>&nbsp;

Press Release

Eva Pharma Granted License to Manufacture and Distribute “Remdesivir” in 127 countries

Are you a Healthcare professional?

Eva Pharma Granted License to Manufacture and Distribute “Remdesivir” in 127 countries

24 June, 2020

Eva Pharma Granted License to Manufacture and Distribute “Remdesivir” in 127 countries

24 June, 2020

Find out more about EVA Pharma

EVA Pharma’s roots stretch back over a hundred years.

Our experienced leadership team keeps us on track.

EVA Pharma’s success is based on its dynamic team, Our people are our power.